Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intravitreal Injection Patients Clear all
Completed No phase listed Observational

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT04340505
View directory record Official record
Conditions
Uveitis
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 6:43 PM EDT
Recruiting Phase 3 Interventional

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
54
States / cities
Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

NCT02288559
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Sham, Lampalizumab
Other · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 22, 2026, 6:43 PM EDT
Withdrawn Phase 4 Interventional

Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye

NCT04702048
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Aflibercept Injection, Sham injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 4 Interventional

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

NCT00690313
View directory record Official record
Conditions
Intravitreal Injection Patients
Interventions
Vigamox
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 22, 2026, 6:43 PM EDT
Withdrawn Phase 4 Interventional

Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment

NCT01495208
View directory record Official record
Conditions
Fibrovascular Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Not applicable Interventional

30g vs 33g Needle for Intravitreal Injections

NCT03038048
View directory record Official record
Conditions
Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Varying needle size with intravitreal ranibizumab or aflibercept
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1
Drug
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT03295877
View directory record Official record
Conditions
Geographic Atrophy
Interventions
RO7171009
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Bakersfield, California • Mountain View, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

NCT00395057
View directory record Official record
Conditions
Choroid Neovascularization, Age-Related Macular Degeneration
Interventions
AGN 211745, Ranibizumab 500µg
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

NCT05643118
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Genetic
Lead sponsor
Olix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

NCT04278417
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 22, 2026, 6:43 PM EDT
Withdrawn Phase 4 Interventional

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

NCT03059277
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
EYE001 anti-VEGF aptamer
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections

NCT01027611
View directory record Official record
Conditions
Pain
Interventions
proparacaine HCL 0.5%, proparacaine HCL 0.5% + 4% lidocaine solution, 3.5% viscous lidocaine gel
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525600
View directory record Official record
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
73
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 22, 2026, 6:43 PM EDT
Not listed Early Phase 1 Interventional

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

NCT03571100
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Jul 22, 2026, 6:43 PM EDT
Completed No phase listed Observational

REALITY LHON Registry

NCT03295071
View directory record Official record
Conditions
Leber Hereditary Optic Neuropathy
Interventions
Patient-reported outcomes (PROs)
Other
Lead sponsor
GenSight Biologics
Industry
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Pasadena, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT00363714
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
AGN211745
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Jul 22, 2026, 6:43 PM EDT
Active, not recruiting Phase 3 Interventional

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988
View directory record Official record
Conditions
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
91
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 22, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

NCT01229215
View directory record Official record
Conditions
Geographic Atrophy
Interventions
FCFD4514S, sham
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years to 89 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
30
States / cities
Tucson, Arizona • Beverly Hills, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 22, 2026, 6:43 PM EDT